口服抗凝药达比加群导致的出血与心房颤动患者的隐匿性癌症高度相关。
Bleeding with oral anticoagulant dabigatran is highly associated with occult cancers in atrial fibrillation patients.
作者信息
Koike Hideki, Fujino Tadashi, Koike Makiko, Yao Shintaro, Akitsu Katsuya, Shinohara Masaya, Yuzawa Hitomi, Suzuki Takeya, Ikeda Takanori
机构信息
Department of Cardiovascular Medicine, Toho University Graduate School of Medicine, Tokyo, Japan.
出版信息
Future Cardiol. 2018 Jan;14(1):27-36. doi: 10.2217/fca-2017-0063. Epub 2017 Dec 4.
AIM
The aim of this study was to examine cancer and bleeding in atrial fibrillation patients administered with dabigatran.
MATERIALS & METHODS: This study enrolled 509 consecutive nonvalvular atrial fibrillation patients who received dabigatran. The mean administration period was 14.8 ± 15.7 months. We investigated the prevalence and new development of cancers. Further, the relation between cancer and adverse events was evaluated.
RESULTS
In the 509 patients, major bleeding occurred in 2.6% and dyspepsia in 8.4%. Further, 16.9% patients had a history of cancer and 3.9% developed new cancers. These adverse events developed in 45% patients who developed new cancers. The cancer (hazard ratio: 6.30; p = 0.003) was a significant predictor of major bleeding.
CONCLUSION
Bleeding was associated with the presence of cancer.
目的
本研究旨在探讨接受达比加群治疗的心房颤动患者的癌症和出血情况。
材料与方法
本研究纳入了509例连续接受达比加群治疗的非瓣膜性心房颤动患者。平均给药期为14.8±15.7个月。我们调查了癌症的患病率和新发病例。此外，评估了癌症与不良事件之间的关系。
结果
在509例患者中，严重出血发生率为2.6%，消化不良发生率为8.4%。此外，16.9%的患者有癌症病史，3.9%的患者出现了新发癌症。这些不良事件发生在45%出现新发癌症的患者中。癌症（风险比：6.30；p = 0.003）是严重出血的重要预测因素。
结论
出血与癌症的存在有关。
Zotero 插件